Harnessing Nanoparticles to Enhance Therapeutic Efficacy in Oral Cancer Management

A significant worldwide health issue, oral cancer (OC) is marked by high death rates that are ascribed to delayed detection and the limitations of conventional treatment approaches. Oral squamous cell carcinoma (OSCC) among OCs has become a prominent cancer in humans that is likely to deteriorate, as its prevalence is projected to rise by 65% by 2050, with an anticipated annual worldwide occurrence of approximately 389,000 newly diagnosed subjects. Some OSCC patients still lose out on the chance for a complete tumor excision despite advancements in clinical care, and when the cancer progresses to an advanced stage, they must accept medicinal interventions such as radiation therapy, chemotherapy, or immunotherapy. However, because of the poor effectiveness of traditional administration methods, these treatments have been described as being far from optimal. To increase the therapeutic effects, an abundance of investigations have been conducted into developing an effective drug delivery system (DDS). The best DDS candidates have been determined to be nanostructures, which can particularly aggregate in the microenvironment of the tumor, coupled with a significant number of blood vessels. According to new research, NPs containing anticancer medications, such as radiation treatments, chemotherapy, and antibodies for targeting the immune system, can substantially increase the dosage and release of such medications at the location of the tumor and exhibit superior efficacy for treatment. This suggests that NPs could be a potential DDS for the OSCC and OC management.